Digital PET/CT with ¹⁸F-FACBC in early castration-resistant prostate cancer: our preliminary results

References

• Saad F, Bögemann M, Suzuki K, et al. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021;24:323–334.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. JCO. 2016;34:1402–1418.
   PubMed Web of Science ®Google Scholar
• Cattrini C, Caffo O, De Giorgi U, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel). 2022;14:1792.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378:1408–1418.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–2474.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, Castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–1246.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Koo PJ, Shore N, et al. A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III). J Urol. 2019;201:682–692.
   PubMed Web of Science ®Google Scholar
• Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:7448–7454.
   PubMed Web of Science ®Google Scholar
• Weber M, Kurek C, Barbato F, et al. PSMA-ligand pet for early castration-resistant prostate cancer: a retrospective single-center study. J Nucl Med. 2021;62:88–91.
   PubMed Web of Science ®Google Scholar
• Filippi L, Bagni O, Crisafulli C, et al. Detection rate and clinical impact of PET/CT with 18F-FACBC in patients with biochemical recurrence of prostate cancer: a retrospective bicentric study. Biomedicines. 2022;10:177.
   PubMed Web of Science ®Google Scholar
• Pernthaler B, Kulnik R, Gstettner C, et al. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT. Clin Nucl Med. 2019;44:e566–73.
   PubMed Web of Science ®Google Scholar
• Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–1294.
   PubMed Web of Science ®Google Scholar
• Amorim BJ, Prabhu V, Marco SS, et al. Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:105–114.
   PubMedGoogle Scholar
• Delcroix O, Bourhis D, Keromnes N, et al. Assessment of image quality and lesion detectability with digital PET/CT system. Front Med. 2021;8:629096.
   PubMed Web of Science ®Google Scholar
• Nanni C, Zanoni L, Bach-Gansmo T, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0. Eur J Nucl Med Mol Imaging. 2020;47:579–591.
   PubMed Web of Science ®Google Scholar
• Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59:469–478.
   PubMedGoogle Scholar
• Cetin B, Wabl CA, Gumusay O. Optimal treatment for patients with oligometastatic prostate cancer. Urol Int. 2022;106:217–226.
   PubMed Web of Science ®Google Scholar
• Farolfi A, Hirmas N, Gafita A, et al. Identification of PCWG3 target populations is more accurate and reproducible with psma pet than with conventional imaging: a multicenter retrospective study. J Nucl Med. 2021;62(5):675–678.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Kostakoglu L, Chau A, et al. The impact of positron emission tomography with 18 F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 2019;201:322–331.
   PubMed Web of Science ®Google Scholar
• Falcon B, Zivanov J, Zhang W, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420–423.
   PubMed Web of Science ®Google Scholar
• Anand A, Heller G, Fox J, et al. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022;20:270–277.
   PubMed Web of Science ®Google Scholar
• Dore F, Filippi L. Reply: bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009;50:1385.2–1385.
   Web of Science ®Google Scholar
• Wolff JM, Bares R, Jung PK, et al. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int. 1996;56:169–173.
   PubMed Web of Science ®Google Scholar
• Vaz SC, Oliveira F, Herrmann K, et al. Nuclear medicine and molecular imaging advances in the 21st century. BJR. 2020;93:20200095.
   Google Scholar
• Fabbri A, Cencelli VO, Bennati P, et al. Dual isotope imaging with LaBr3:Ce crystal and H8500 PSPMT. J Inst. 2013;8. C02022–C02022.
   Web of Science ®Google Scholar
• Schillaci O, Urbano N. Digital PET/CT: a new intriguing chance for clinical nuclear medicine and personalized molecular imaging. Eur J Nucl Med Mol Imaging. 2019;46:1222–1225.
   PubMed Web of Science ®Google Scholar
• van Sluis J, de Jong J, Schaar J, et al. Performance characteristics of the digital biograph vision PET/CT system. J Nucl Med. 2019;60:1031–1036.
   PubMed Web of Science ®Google Scholar
• Katal S, Eibschutz LS, Saboury B, et al. Advantages and applications of total-body PET scanning. Diagnostics. 2022;12:426.
   Web of Science ®Google Scholar
• Filippi L, Schillaci O. Total-body [18F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true? Eur J Nucl Med Mol Imaging. 2022;49:3322–3327.
   PubMed Web of Science ®Google Scholar
• Alberts I, Hünermund J-N, Sachpekidis C, et al. The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. Eur Radiol. 2021;31:8030–8039.
   PubMed Web of Science ®Google Scholar
• Alberts I, Prenosil G, Sachpekidis C, et al. Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47:614–623.
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. JCO. 2016;34:1402–1418.
   PubMed Web of Science ®Google Scholar
• Moyer CL, Phillips R, Deek MP, et al. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol. 2019;37:2623–2629.
   PubMed Web of Science ®Google Scholar
• Ingrosso G, Detti B, Fodor A, et al. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol. 2021;23:1577–1584.
   PubMed Web of Science ®Google Scholar
• Uprimny C, Kroiss AS, Decristoforo C, et al. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44:765–775.
   PubMed Web of Science ®Google Scholar
• Vollnberg B, Alberts I, Genitsch V, et al. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022;49:3910–3916.
   PubMed Web of Science ®Google Scholar
• Rovera G, Oprea-Lager DE, Ceci F. Health technology assessment for PSMA-PET: striving towards a cost-effective management of prostate cancer. Clin Transl Imaging. 2021;9:409–412.
   Web of Science ®Google Scholar
• Cytawa W, Kircher S, Kübler H, et al. Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. Eur J Nucl Med Mol Imaging. 2022;49:3938–3949.
   PubMed Web of Science ®Google Scholar